Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFRONT-3 phase 3 study of latozinemab in frontotemporal dementia
NL-OMON59907Phase 3Completed
- Sponsor
- Alector
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in frontotemporal dementia (FTD) comparing latozinemab with placebo (2 arms). Primary endpoint: Change from baseline in CDR plus NACC FTLD-SB. Started Oct 2020; status: completed.
02
Drugs
latozinemab
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON59907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59907.